On September 18, HANSOH PHARMA rose 3.09% in regular trading, trading at HK$35.4/share, with turnover of HK$61.56 million. The gain comes amid a series of positive catalysts in recent days.

On September 16, the company announced that its self-developed Class 1 new drug HS-20197 for injection received clinical trial approval from China's NMPA for the treatment of advanced solid tumors. This adds to a string of favorable developments, including the NMPA's acceptance of the biologics license application for HS-20093, a B7-H3 targeted ADC for small cell lung cancer, and its subsequent inclusion in the priority review program based on positive Phase 3 ARTEMIS-008 data showing a median overall survival of 18.5 months versus 10.3 months for topotecan.

Multiple investment banks have recently reiterated bullish ratings, with Goldman Sachs maintaining a Buy rating and a target price of HK$52.7, JPMorgan maintaining Overweight with a HK$50 target, and UBS rating the stock a Buy. The company reported H1 revenue of RMB 8.3 billion, up 11.7% year-over-year, with innovative drug revenue accounting for 85.4% of total revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)